1-20 of 41
Funda Meric-Bernstam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study

Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, Victor Moreno, Yeon Hee Park, Sun Young Rha, Pavani Chalasani, Wei Zhong, Li Zhou, Steven Pirie-Shepherd, Abraham C.F. Leung, Giuseppe Curigliano
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (10): 1191–1203.
https://doi.org/10.1158/1535-7163.MCT-23-0101
Published: 02 October 2023
View article titled, Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Open the PDF for Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study in another window
Includes: Supplementary data
Journal Articles

Discordance of HER2 Expression and/or Amplification on Repeat Testing

Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (8): 976–984.
https://doi.org/10.1158/1535-7163.MCT-22-0630
Published: 01 August 2023
View article titled, Discordance of HER2 Expression and/or Amplification on Repeat Testing
Open the PDF for Discordance of HER2 Expression and/or Amplification on Repeat Testing in another window
Includes: Supplementary data
Journal Articles

Abstract P047: A phase 1/2 trial of CBX-12, an alphalexTM peptide drug conjugate, in patients with advanced or metastatic refractory solid tumors

Anthony Tolcher, Joseph Paul Eder, David Sommerhalder, Sophia Gayle, Paul Pearson, Deb Chapman, Arthur P. DeCillis, Anish Thomas, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P047.
https://doi.org/10.1158/1535-7163.TARG-21-P047
Published: 01 December 2021
View article titled, Abstract P047: A phase 1/2 trial of CBX-12, an alphalex<sup>TM</sup> peptide drug conjugate, in patients with advanced or metastatic refractory solid tumors
Journal Articles

Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations

Christian X. Cruz Pico, Dali Li, Christopher D. Lanier, Kurt Evans, Maria G. Raso, Timothy DiPeri, Yasmeen Rizvi, Min Jin Ha, Huiqin Chen, Ming Zhao, Argun Akcakanat, Xiaofeng Zheng, Gokce Toruner, Erkan Yuca, Stephen Scott, Antje M. Wengner, Timothy A. Yap, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P058.
https://doi.org/10.1158/1535-7163.TARG-21-P058
Published: 01 December 2021
View article titled, Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations
Journal Articles

Abstract C080: The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models

Seyed Pairawan, Kurt Evans, Scott Kopetz, Argun Akcakanat, Ming Zhao, Coya Tapia, Naifa Busaidy, Ecaterina Dumbrava, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C080.
https://doi.org/10.1158/1535-7163.TARG-19-C080
Published: 01 December 2019
View article titled, Abstract C080: The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models
Journal Articles

Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer

Kurt Evans, Stacy Moulder, Erkan Yuca, Stephen Scott, Natalia Paez Arango, Maryam Shariati, Christopher P Vellano, Turcin Saridogan, Xiaofeng Zheng, Ana Maria Gonzalez-Angulo, Ming Zhao, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akcakanat, Charles M Perou, Bora Lim, Debu Tripathy, Timothy A Yap, Maria E Di Francesco, Giulio Draetta, Philip Jones, Joe Marszalek, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C016.
https://doi.org/10.1158/1535-7163.TARG-19-C016
Published: 01 December 2019
View article titled, Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer
Journal Articles

Abstract B104: Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations

Maryam Shariati, Christopher A Bristow, Alessandro Carugo, Tim Heffernan, Xiaofeng Zheng, Michael D Peoples, Debu Tripathy, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B104.
https://doi.org/10.1158/1535-7163.TARG-19-B104
Published: 01 December 2019
View article titled, Abstract B104: Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with <em>PIK3CA/AKT1</em> mutations
Journal Articles

Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas

Geraldine O'Sullivan Coyne, Timothy A Yap, Nancy Moore, Arjun Mittra, Naoko Takebe, Lamin Juwara, Sabrina Khan, Ecaterina Ileana Dumbrava, Howard Streicher, Richard Piekarz, Elad Sharon, Funda Meric-Bernstam, Ralph Parchment, Tony Navas, King Leung Fung, James Mitchell, Kristin Fino, Sandra Montez, Austin Doyle, Laurence Rubinstein, James H Doroshow, Alice P Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B105.
https://doi.org/10.1158/1535-7163.TARG-19-B105
Published: 01 December 2019
View article titled, Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas
Journal Articles

Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer

Ming Zhao, Stephen Scott, Kurt Evans, Erkan Yuca, Turcin Saridogan, Mehmet E Demirhan, Bryce P Kirby, Scott Kopetz, Irmina Diala, Alshad S Lalani, Sarina A Piha-Paul, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B003.
https://doi.org/10.1158/1535-7163.TARG-19-B003
Published: 01 December 2019
View article titled, Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer
Journal Articles

Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer

Funda Meric-Bernstam, Jorge Chaves, Do-Youn Oh, Jeeyun Lee, Yoon-Koo Kang, Erika Hamilton, Jose Mayordomo, Melody Cobleigh, Christos Vaklavas, Elena Elimova, Jaffer Ajani, Jordi Rodon, Gerry Rowse, Todd Gray, Rose Lai, Diana Hanna
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B001.
https://doi.org/10.1158/1535-7163.TARG-19-B001
Published: 01 December 2019
View article titled, Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer
Journal Articles

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, Eli L. Diamond, Aaron M. Goodman, Vaijayanthi Kandadai Raghavan, Tamara G. Barnes, Shumei Kato, Omar Abdel-Wahab, Benjamin H. Durham, Funda Meric-Bernstam, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (6): 1149–1157.
https://doi.org/10.1158/1535-7163.MCT-18-1244
Published: 03 June 2019
View article titled, Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis
Open the PDF for Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis in another window
Journal Articles

Prospective Clinical Sequencing of Adult Glioma

Siyuan Zheng, Kristin Alfaro-Munoz, Wei Wei, Xiaojing Wang, Fang Wang, Agda Karina Eterovic, Kenna R. Mills Shaw, Funda Meric-Bernstam, Gregory N. Fuller, Ken Chen, Roel G. Verhaak, Gordon B. Mills, W.K. Alfred Yung, Shiao-Pei Weathers, John F. de Groot
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (5): 991–1000.
https://doi.org/10.1158/1535-7163.MCT-18-1122
Published: 01 May 2019
View article titled, Prospective Clinical Sequencing of Adult Glioma
Open the PDF for Prospective Clinical Sequencing of Adult Glioma in another window
Includes: Supplementary data
Journal Articles

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers

Roman Groisberg, David S. Hong, Jason Roszik, Filip Janku, Apostolia M. Tsimberidou, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (7): 1595–1601.
https://doi.org/10.1158/1535-7163.MCT-17-1107
Published: 01 July 2018
View article titled, Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Open the PDF for Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers in another window
Journal Articles

Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors

Ecaterina Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, Milind Javle, Mariela Blum-Murphy, Blessy Sajan, Scott Kopetz, Russell Broaddus, Mark Routbort, Shubham Pant, Apostolia Tsimberidou, Vivek Subbiah, David S. Hong, Jordi Rodon Ahnert, Kenna Shaw, Sarina Piha-Paul, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A167.
https://doi.org/10.1158/1535-7163.TARG-17-A167
Published: 01 January 2018
View article titled, Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors
Journal Articles

Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose

Shiraj Sen, David S. Hong, Kenneth Hess, Funda Meric-Bernstam, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A199.
https://doi.org/10.1158/1535-7163.TARG-17-A199
Published: 01 January 2018
View article titled, Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose
Journal Articles

Abstract LB-B22: TNBC kinase prioritization for targeted therapy after chemotherapy resistance

Bora Lim, In Ah Park, Ying Wang, Lakshmi Bollu, Powel Brown, Keith Baggerly, Funda Meric-Bernstam, Naoto Ueno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B22.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B22
Published: 01 January 2018
View article titled, Abstract LB-B22: TNBC kinase prioritization for targeted therapy after chemotherapy resistance
Journal Articles

Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

Sarina A. Piha-Paul, Wendy Wen Xiong, Tyler Moss, Rosa M. Mostorino, Shelby Sedelmeier, Kenneth Hess, Siqing Fu, David Hong, Filip Janku, Daniel Karp, Aung Naing, Shubham Pant, Jordi Rodon, Vivek Subbiah, A M. Tsimberidou, Timothy Yap, Milind Javle, Coya Tapia, Kenna R. Shaw, Karina Eterovic, Gordon B. Mills, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A096.
https://doi.org/10.1158/1535-7163.TARG-17-A096
Published: 01 January 2018
View article titled, Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in <em>BRCA1/2</em>, mutations/deletions in <em>PTEN</em> or PTEN loss, aberrations in other <em>BRCA</em> pathway genes, and germline mutations in <em>BRCA1/2</em> (not breast or ovarian cancer)
Journal Articles

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Filip Janku, Helen J. Huang, Bart Claes, Gerald S. Falchook, Siqing Fu, David Hong, Nishma M. Ramzanali, Giovanni Nitti, Goran Cabrilo, Apostolia M. Tsimberidou, Aung Naing, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Veronica R. Holley, Ralph G. Zinner, Vivek Subbiah, Rajyalakshmi Luthra, Scott Kopetz, Michael J. Overman, Bryan K. Kee, Sapna Patel, Benoit Devogelaere, Erwin Sablon, Geert Maertens, Gordon B. Mills, Razelle Kurzrock, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1397–1404.
https://doi.org/10.1158/1535-7163.MCT-15-0712
Published: 02 June 2016
View article titled, <em>BRAF</em> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
Open the PDF for <em>BRAF</em> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System in another window
Includes: Supplementary data
Journal Articles

Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer

Vivek Subbiah, David S. Hong, Behrang Amini, Sarina Piha-Paul, Joanna Grace Fernandez, Siquing Fu, Apostolia M. Tsimberidou, Aung Naing, Filip Janku, Daniel D. Karp, Michael Overman, Cathy Eng, Scott Kopetz, Funda Meric-Bernstam, Gerald S. Falchook
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C50.
https://doi.org/10.1158/1535-7163.TARG-15-C50
Published: 01 December 2015
View article titled, Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer
Journal Articles

Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations

Tina Cascone, Kenneth R. Hess, Sarina Piha-Paul, David S. Hong, Michael Roxas, Ishwaria M. Subbiah, Siquing Fu, Aung Naing, Filip Janku, Daniel Karp, Steven I. Sherman, Funda Meric-Bernstam, John V. Heymach, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C17.
https://doi.org/10.1158/1535-7163.TARG-15-LB-C17
Published: 01 December 2015
View article titled, Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations